Isn't the question why is is it taking so much time.

I believe it is taking so much time is because it takes a significant amount of proof.

That proof is not yet evident. We have what seems to be remarkable post hocs re CVD, CKD and many other inflammatory conditions. However, we have almost zero information on 3 point MACE. 

We know that apabetalone has a multi modal MOA of at least 6 biological mechanisms based on the post hocs. This seems very positive. Yet the FA of BoM must be passed for this particular trial.

Perhaps apabetalone has some sort of gentle impact like something that one could just buy over the drug counter without a subsbcribtion? Who knows.

I guess, at the end of the day, BP has not jumped in. BP are conservative and they have thousands of little companies like RVX to review.

Innovation is very difficult to evaluate. And risk is not something that BP is comfortable with.

I do think that RVX will make it through this financing. The science is too good but unproven.

Just my foolish opinions.

GLTA 

TOINV